Values First Advisors Inc. bought a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 6,322 shares of the company’s stock, valued at approximately $568,000.
A number of other institutional investors also recently made changes to their positions in the business. Natixis raised its position in shares of Axsome Therapeutics by 13.6% in the 1st quarter. Natixis now owns 1,235 shares of the company’s stock valued at $99,000 after purchasing an additional 148 shares in the last quarter. Arizona State Retirement System raised its position in shares of Axsome Therapeutics by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 8,630 shares of the company’s stock valued at $695,000 after purchasing an additional 177 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Axsome Therapeutics by 2.9% in the 1st quarter. Principal Financial Group Inc. now owns 9,773 shares of the company’s stock valued at $780,000 after purchasing an additional 276 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Axsome Therapeutics in the 2nd quarter valued at approximately $27,000. Finally, Oak Ridge Investments LLC raised its position in shares of Axsome Therapeutics by 2.7% in the 1st quarter. Oak Ridge Investments LLC now owns 15,930 shares of the company’s stock valued at $1,271,000 after purchasing an additional 413 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Axsome Therapeutics
In related news, Director Mark E. Saad sold 11,016 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares of the company’s stock, valued at $913,282.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Mark E. Saad sold 11,016 shares of the stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the sale, the director now directly owns 10,002 shares of the company’s stock, valued at approximately $913,282.62. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Mark L. Jacobson sold 47,739 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $84.26, for a total value of $4,022,488.14. Following the completion of the sale, the chief operating officer now directly owns 5,783 shares of the company’s stock, valued at approximately $487,275.58. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 22.40% of the company’s stock.
Axsome Therapeutics Trading Down 3.8 %
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.06. Axsome Therapeutics had a negative return on equity of 117.46% and a negative net margin of 105.85%. The company had revenue of $87.17 million during the quarter, compared to analysts’ expectations of $84.53 million. Equities analysts predict that Axsome Therapeutics, Inc. will post -4.73 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Bank of America raised Axsome Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $95.00 to $106.00 in a research report on Tuesday, August 6th. Wells Fargo & Company initiated coverage on Axsome Therapeutics in a research report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Axsome Therapeutics in a research report on Monday, September 16th. Royal Bank of Canada upped their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Finally, Needham & Company LLC reissued a “buy” rating and set a $130.00 price target on shares of Axsome Therapeutics in a research report on Thursday, September 5th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $124.64.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
See Also
- Five stocks we like better than Axsome Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is an Earnings Surprise?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 3 Tickers Leading a Meme Stock Revival
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.